Efficacy of Cefcapene Pivoxil for Empirical Therapy of Acute Uncomplicated Cystitis.
- Author:
Seung Ju LEE
1
;
U Syn HA
;
Hyun Woo KIM
;
Yong Hyun CHO
Author Information
- Publication Type:Original Article
- Keywords: Cefcapene pivoxil; Acute uncomplicated cystitis
- MeSH: Cystitis; Fluoroquinolones; Humans; Korea; Prevalence; Prospective Studies
- From: Infection and Chemotherapy 2008;40(3):162-166
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: A high prevalence of fluoroquinolone resistance among uropathogens has been observed in Korea. Since empirical antimicrobial therapy should be guided by the proportion of pathogens resistant to the chosen antibiotic, the limitation of fluoroquinolones as the first empirical choice for acute cystitis is noticed in the clinical setting. The present study was undertaken to determine the susceptibility profiles of urinary isolates to cefcapene pivoxil and assess the clinical efficacy in patients with acute uncomplicated cystitis. MATERIALS AND METHODS: The study was a prospective, open label, non-comparative, non-blinded trial. Ninety-two patients with acute, uncomplicated symptomatic cystitis from two hospitals were treated with cefcapene pivoxil 100 mg tid for 5 days and followed up for 2 weeks. RESULTS: Seventy-seven of the 92 patients were evaluated. Bacteriological eradication of initial pathogens was achieved in 97.4% by 2 weeks after therapy termination. Seventy-four of 77 (96.1%) patients were symptomatically cured or improved after completion of therapy. Drug related adverse experiences were seen in 8 patients. None necessitated cessation of therapy. No significant biochemical or hematological abnormalities occurred. CONCLUSION: These results demonstrate the clinical efficacy and safety of empirical 5-day cefcapene pivoxil for acute uncomplicated cystitis.
